HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a $90 price target. This reaffirms the firm's positive outlook on the company.
March 26, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Viking Therapeutics with a $90 price target, indicating a strong positive outlook on the company's future.
The reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100